Published in Drug Week, November 15th, 2002
This multicenter trial will be conducted by a national U.S. cooperative study group, the Cancer and Leukemia Group B (CALGB), and will be sponsored by the U.S. National Cancer Institute, pursuant to Genta's Cooperative Research and Development Agreement (CRADA).
Gleevec was approved in record time in 2001 for the treatment of CML. Despite a large number of early responses, however, resistance...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week